The applying from Lykos — a drug enterprise incubated from the Multidisciplinary Association for Psychedelic Experiments, or MAPS — arrived with the FDA under a cloud of controversy. Former trial contributors experienced alleged adverse events were not claimed — together with thoughts of suicidality after the treatment method — and that bia